With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1204-75-7,3-Oxo-3,4-dihydroquinoxaline-2-carboxylic acid,as a common compound, the synthetic route is as follows.
The resulting compound (737 mg, 1.80 mmol) was condensed with 3-hydroxyquinoxaline-2-carboxylic acid (353 mg, 1.80 mmol) to afford the desired title compound (609 mg, yield 62%) as a pale yellow solid. 1H-NMR (DMSO-d6, 400 MHz) delta: 12.83 (1H, brs), 9.50 (1H, d, J=9.0 Hz), 7.90-7.84 (1H, m), 7.69-7.62 (1H, m), 7.60-7.53 (1H, m), 7.41-7.35 (2H, m), 7.33-7.20 (2H, m), 4.91 (1H, m), 4.74 (1H, m), 3.92-3.41 (4H, m), 3.92-3.41 (5H, m), 0.96 and 0.95 (6H, d, J=6.2 Hz). IR (KBr) cm-1: 2960, 1690, 1630, 1530, 1485, 1190. MS (ESI, m/z): 545 (M+H)+; HRMS (ESI, m/z): 545.1210 (Calcd for C25H27BrFN4O4: 545.1200).
1204-75-7, The synthetic route of 1204-75-7 has been constantly updated, and we look forward to future research findings.
Reference£º
Patent; Daiichi Sankyo Company, Limited; EP2258697; (2010); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider